Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.49
-0.05 (-0.59%)
At close: Dec 20, 2024, 4:00 PM
8.40
-0.09 (-1.06%)
After-hours: Dec 20, 2024, 4:34 PM EST
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $3.70M in the quarter ending September 30, 2024, with 27.63% growth. This brings the company's revenue in the last twelve months to $24.49M, up 47.85% year-over-year. In the year 2023, Zevra Therapeutics had annual revenue of $27.46M with 170.26% growth.
Revenue (ttm)
$24.49M
Revenue Growth
+47.85%
P/S Ratio
14.76
Revenue / Employee
$354,913
Employees
69
Market Cap
453.16M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
Dec 31, 2019 | 12.84M | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
InnovAge Holding | 786.51M |
DocGo | 694.97M |
Ginkgo Bioworks Holdings | 217.95M |
UroGen Pharma | 89.36M |
AnaptysBio | 57.17M |
MeiraGTx Holdings | 13.93M |
ZVRA News
- 4 days ago - Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 - GlobeNewsWire
- 15 days ago - Zevra Therapeutics Announces Organizational Changes - GlobeNewsWire
- 25 days ago - Zevra Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 5 weeks ago - Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - GlobeNewsWire